Zeo ScientifiX (ZEOX) 10-Q 17 Mar 21 2021 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Jan. 31, 2021	Mar. 16, 2021
Document And Entity Information
Entity Registrant Name	Organicell Regenerative Medicine, Inc.
Entity Central Index Key	0001557376
Document Type	10-Q
Document Period End Date	Jan. 31, 2021
Amendment Flag	false
Current Fiscal Year End Date	--10-31
Entity's Reporting Status Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		1,041,341,874
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021
Entity File Number	000-55008
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	NV

CONSOLIDATED BALANCE SHEETS (Un

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Jan. 31, 2021	Oct. 31, 2020
Current Assets
Cash	$ 66,814	$ 590,797
Accounts receivable, net of allowance for bad debts	59,290	29,385
Prepaid expenses	80,305	78,790
Inventories	148,423	146,811
Total Current Assets	354,832	845,783
Property and equipment, net	399,306	365,234
Other assets - right of use	96,005	105,355
Security deposits	20,782	17,800
TOTAL ASSETS	870,925	1,334,172
Current Liabilities
Accounts payable and accrued expenses	1,585,605	765,652
Accrued liabilities to management	1,403,699	1,156,295
Notes payable	4,392	6,949
Advances from affiliate	220,897	220,897
Finance lease obligations	55,318	50,843
Operating lease obligations	38,037	38,037
Convertible debentures	150,250	175,000
Liabilities attributable to discontinued operations	125,851	125,851
Total Current Liabilities	3,584,049	2,539,524
Long term finance lease obligations	107,024	119,146
Long term operating lease obligations	57,968	67,318
Total Liabilities	3,749,041	2,725,988
Stockholders' Deficit
Common stock, $0.001 par value, 2,500,000,000 shares authorized; 1,010,132,783 and 939,942,783 shares issued and outstanding, respectively	1,010,133	939,943
Additional paid-in capital	33,129,945	26,536,430
Accumulated deficit	(37,018,194)	(28,868,189)
Total Stockholders' Deficit	(2,878,116)	(1,391,816)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 870,925	$ 1,334,172

CONSOLIDATED BALANCE SHEETS (_2

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Jan. 31, 2021	Oct. 31, 2020
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	2,500,000,000	2,500,000,000
Common stock, shares issued	1,010,132,783	939,942,783
Common stock, shares outstanding	1,010,132,783	939,942,783

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Jan. 31, 2021	Jan. 31, 2020
Income Statement [Abstract]
Revenues	$ 1,368,440	$ 696,948
Cost of revenues	168,171	99,720
Gross profit	1,200,269	597,228
General and administrative expenses	9,365,630	1,286,013
Loss from operations	(8,165,361)	(688,785)
Other income (expense)
Interest expense	(6,209)	(23,513)
Other	21,565	15,857
Loss before taxes	(8,150,005)	(696,441)
Provision for income taxes	0	0
Net loss	$ (8,150,005)	$ (696,441)
Net loss per common share - basic and diluted	$ (0.01)	$ 0
Weighted average number of common shares outstanding - basic and diluted	966,563,218	505,054,740

CONSOLIDATED CHANGES TO STOCKHO

CONSOLIDATED CHANGES TO STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at beginning, value at Oct. 31, 2019	$ 502,937	$ 14,219,736	$ (16,285,222)	$ (1,562,549)
Balance at beginning, shares at Oct. 31, 2019	502,936,805
Sale of common stock, value	$ 3,250	61,750		65,000
Sale of common stock, shares	3,250,000
Stock-based compensation, value	$ 2,650	90,834		93,484
Stock-based compensation, shares	2,650,000
Net loss			(696,441)	(696,441)
Balance at end, value at Jan. 31, 2020	$ 508,837	14,372,320	(16,981,663)	(2,100,506)
Balance at end, shares at Jan. 31, 2020	508,836,805
Balance at beginning, value at Oct. 31, 2020	$ 939,943	26,536,430	(28,868,189)	(1,391,816)
Balance at beginning, shares at Oct. 31, 2020	939,942,783
Sale of common stock, value	$ 800	39,200		40,000
Sale of common stock, shares	800,000
Stock-based compensation, value	$ 69,390	6,554,315		6,623,705
Stock-based compensation, shares	69,390,000
Net loss			(8,150,005)	(8,150,005)
Balance at end, value at Jan. 31, 2021	$ 1,010,133	$ 33,129,945	$ (37,018,194)	$ (2,878,116)
Balance at end, shares at Jan. 31, 2021	1,010,132,783

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Jan. 31, 2021	Jan. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (8,150,005)	$ (696,441)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	12,192	6,434
Stock-based compensation	6,623,705	93,484
Changes in operating assets and liabilities:
Accounts receivable, net of allowance for bad debts	(29,905)	(37,532)
Prepaid expenses	(1,515)	47,003
Inventories	(1,612)	(51,676)
Accounts payable and accrued expenses	819,953	179,223
Accrued liabilities to management	247,404	182,452
Security deposits	(2,982)	0
Net cash used in operating activities	(482,765)	(277,053)
CASH FLOWS FROM INVESTING
Purchase of fixed assets	(46,264)	(28,902)
Net cash used in investing activities	(46,264)	(28,902)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of notes payable	0	300,000
Payments on finance lease	(7,647)	(25,430)
Repayments of notes payable	(27,307)	(23,904)
Proceeds from sale of common stock and warrants	40,000	65,000
Net cash provided by financing activities	5,046	315,666
Increase (decrease) in cash	(523,983)	9,711
Cash at beginning of year	590,797	132,557
Cash at end of year	66,814	142,268
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for taxes	0	0
Cash paid for interest	$ 11,672	$ 25,232

ORGANIZATION AND DESCRIPTION OF

ORGANIZATION AND DESCRIPTION OF BUSINESS	3 Months Ended
	Jan. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS	NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS Organicell Regenerative Medicine, Inc. (formerly Biotech Products Services and Research, Inc.) (“Organicell” or the “Company”) was incorporated on August 9, 2011 in the State of Nevada. The Company is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and to provide other related services. Our proprietary products are derived from perinatal sources and are principally used in the health care industry administered through doctors and clinics (collectively, the “Providers”). On May 21, 2018, the Company filed a Certificate of Amendment with the Secretary of State of Nevada to change the Company’s name from Biotech Products Services and Research, Inc. to Organicell Regenerative Medicine, Inc., effective June 20, 2018 (the “Name Change”). As discussed in Note 12, the Name Change has not yet been effectuated in the marketplace by the Financial Industry Regulatory Agency (“FINRA”). For the three months ended January 31, 2021, the Company principally operated through General Surgical of Florida, Inc., a Florida corporation (“General Surgical”) and wholly owned subsidiary, with a business purpose to sell therapeutic products to Providers. During November 2020, the Company formed Livin Again Inc.(“Livin”), a wholly owned subsidiary of the Company for the purpose of among other things, providing independent education, advertising and marketing services, (“Marketing Services”) to providers that provide medical and other healthcare, anti-aging and regenerative services (“Regenerative Services”) including FDA-approved IV vitamin and mineral liquid infusions (“IV Drip Therapies”). As of January 31, 2021, Livin did not have any significant activity.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Jan. 31, 2021
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The unaudited consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities Exchange Commission, although we believe that the disclosures made are adequate to make the information not misleading. These unaudited consolidated financial statements should be read in conjunction with our Annual Report on Form 10-K for the year ended October 31, 2020 filed with the Securities and Exchange Commission. Concentrations of Credit Risk The balance sheet items that potentially subject us to concentrations of credit risk are primarily cash and cash equivalents. Balances in accounts are insured up to Federal Deposit Insurance Corporation (“FDIC”) limits of $250,000 per institution. At January 31, 2021, the Company did not hold cash balances in any financial institution in excess of FDIC insurance coverage limits. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles of the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Management bases its estimates on historical experience and on other assumptions considered to be reasonable under the circumstances. However, actual results may differ from the estimates. Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Accounts Receivable Accounts receivable are recorded at fair value on the date revenue is recognized. The Company provides allowances for doubtful accounts for estimated losses resulting from the inability of its customers to pay their obligation. If the financial condition of the Company's customers were to deteriorate, resulting in an impairment of their ability to repay, additional allowances may be required. The Company provides for potential uncollectible accounts receivable based on specific customer identification and historical collection experience adjusted for existing market conditions. The policy for determining past due status is based on the contractual payment terms of each customer, which are generally net 30 or net 60 days. Once collection efforts by the Company and its collection agency are exhausted, the determination for charging off uncollectible receivables is made. For the three months ended January 31, 2021 and 2020, the Company did not record any bad debt expense. Inventory Inventory is stated at the lower of cost or net realizable value using the average cost method. The Company provides reserves for potential excess, dated or obsolete inventories based on an analysis of forecasted demand compared to quantities on hand and any firm purchase orders, as well as product shelf life. At January 31, 2021, the Company determined that there were not any reserves required in connection with our finished goods. Property and Equipment Property and equipment are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives of property and equipment range from 3 to 15 years. Upon sale or retirement, the cost and related accumulated depreciation and amortization are eliminated from their respective accounts, and the resulting gain or loss is included in results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred. Revenue Recognition The Company follows the guidance of FASB Accounting Standards Update (“ASU”) Topic 606 “Revenue from Contracts with Customers” which requires the Company to recognize revenue in amounts that reflect the prorata completion of the performance obligations of the Company required under the contracts. The Company applied the new standard using a modified retrospective approach. The Company recognizes revenue only when it transfers control of a promised good or service to a customer in an amount that reflects the consideration it expects to receive in exchange for the good or service. Our performance obligations are satisfied and control is transferred at a point-in-time, which is typically when the transfer and title to the product sold has taken place and there is evidence of our customer’s satisfactory acceptance of the product shipment or delivery. Net Income (Loss) Per Common Share Basic income (loss) per common share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted average number of shares adjusted for any potentially dilutive debt or equity. At January 31, 2021, the Company had 9,500,000 common shares issuable upon the exercise of warrants that were not included in the computation of dilutive loss per share because their inclusion is anti-dilutive for the three months ended January 31, 2021. At January 31, 2020, the Company had 3,257,943 common shares issuable upon the exercise of warrants that were not included in the computation of dilutive loss per share because their inclusion is anti-dilutive for the three months ended January 31, 2020. Stock-Based Compensation All share-based payments to employees, including grants of employee stock options, are recognized in the financial statements based on their fair values. Stock options and warrants issued to consultants and other non-employees as compensation for services provided to the Company are accounted for based upon the estimated fair value of the option or warrant. Research and Development Costs Research and development costs consist of direct and indirect costs associated with the development of the Company’s technologies. These costs are expensed as incurred. Our research and development expenses were approximately $662,000 and $72,000 for the three months ended January 31, 2021 and 2020, respectively. The research and development costs primarily relate to the filing and approval of IND applications and the performance of clinical trials. Income Taxes The Company is required to file a consolidated tax return that includes all of its subsidiaries. Provisions for income taxes are based on taxes payable or refundable for the current year taxable income for federal and state income tax reporting purposes and deferred income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss carryforwards. Deferred income tax expense represents the change during the period in the deferred tax assets and deferred tax liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of the operations in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with FASB Topic 740 – Income Taxes. This pronouncement prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. The interpretation also provides guidance on recognition, derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. For the three months ended January 31, 2021 and 2020 the Company incurred operating losses, and therefore, there was not any income tax expense amount recorded during that period. There is a full valuation allowance established for the tax benefit associated with the net losses for the three months ended January 31, 2021 and 2020. Valuation of Derivatives The Company evaluates its convertible instruments, options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under ASC Topic 815, “Derivatives and Hedging.” The result of this accounting treatment is that the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income (expense). Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Equity instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815 are reclassified to liabilities at the fair value of the instrument on the reclassification date. Sequencing The Company has adopted a sequencing policy whereby, in the event that reclassification of contracts from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of shares. The Company currently has 2,500,000,000 authorized shares of common stock of which 1,041,341,874 shares are issued and outstanding. The Company expects that it will continue to issue common stock in the future in connection with debt and/or equity financings, transactions with third parties, performance incentives and as compensation to its employees. Currently the amount of authorized shares is sufficient to provide for the additional shares that the Company may be contingently obligated to issue under existing arrangements. Fair Value of Financial Instruments The Company includes fair value information in the notes to financial statements when the fair value of its financial instruments is different from the book value. When the book value approximates fair value, no additional disclosure is made. The Company follows FASB ASC 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value and enhances disclosures about fair value measurements. It defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company’s financial instruments consist of cash and cash equivalents, accounts payable, accrued liabilities and convertible debt. The estimated fair value of cash, accounts payable and accrued liabilities approximate their carrying amounts due to the short-term nature of these instruments. The Company follows the provisions of ASC 820 with respect to its financial instruments. As required by ASC 820, assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. Level one Level two Level three The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. The Company did not have any convertible instruments outstanding at January 31, 2021 and October 31, 2020 that qualify as derivatives. Operating and Finance Lease Obligations Effective November 1, 2019, the Company adopted Accounting Standards Update (ASU) No. 2016-02 (Topic 842) (“ASC 842”), that requires organizations that lease assets to recognize assets and liabilities on the balance sheet and provide updated disclosures related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. The Company adopted the new standard using a modified retrospective approach. The modified retrospective approach included a number of optional practical expedients on leases that commenced before the effective date of ASC 842, including continuing to account for leases that commenced before the effective date in accordance with previous guidance, unless the lease is modified. Under the provisions of ASC 842, the Company is required to recognize a right of use (“ROU”) asset and corresponding lease liability for all operating leases upon commencement of the lease. The Company’s policy is to treat operating leases that have a term of one year or less at lease commencement date and do not include a purchase option that is reasonably certain of exercise, consistent with the lease recognition approach as previously outlined under ASC 840. In addition, month to month leases which do not involve additional financial commitments on the part of the Company are also treated consistent with the lease recognition approach as previously outlined under ASC 840. The Company has established a capitalization threshold of $15,000 in determining whether any future operating leases will be capitalized. Subsequent Events The Company has evaluated subsequent events that occurred after January 31, 2021 through the financial statement issuance date for subsequent event disclosure consideration.

GOING CONCERN

GOING CONCERN	3 Months Ended
	Jan. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 3 – GOING CONCERN The unaudited accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. The Company has had limited revenues since its inception. The Company incurred operating losses of $8,165,361 for the three months ended January 31, 2021. In addition, the Company had an accumulated deficit of $37,018,194 at January 31, 2021. The Company had a negative working capital position of $3,229,217 at January 31, 2021. In addition to the above, the outbreak of the novel coronavirus (“COVID-19”) during March 2020 and the resulting adverse public health developments and economic effects to the United States business environments have adversely affected the demand for our products and services by our customers and from patients of our customers as a result of quarantines, facility closures and social distancing measures put into effect in connection with the COVID-19 outbreak and which currently still continue to have a negative impact to our business and the economy. These restrictions have adversely affected the Company’s sales, results of operations and financial condition. In response to the COVID-19 outbreak, the Company (a) has accelerated its research and development activities, (b) is seeking to raise additional debt and/or equity financing to support working capital requirements, and (c) continues to take steps to stabilize and increase revenues from the sale of its products. As a result of the above, the Company’s efforts to establish a stabilized source of sufficient revenues to cover operating costs has yet to be achieved and ultimately may prove to be unsuccessful unless (a) the United States economy resumes to pre-COVID-19 conditions and (b) additional sources of working capital through operations or debt and/or equity financings are realized. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Management anticipates that the Company will remain dependent, for the near future, on additional investment capital to fund ongoing operating expenses and the costs to perform required clinical studies in connection with the sale of its products. The Company does not have any assets to pledge for the purpose of borrowing additional capital. In addition, the Company relies on its ability to produce and sell products it manufactures that are subject to changing technology and regulations that it currently sells and distributes to its customers. The Company’s current market capitalization, common stock liquidity and available authorized shares may hinder its ability to raise equity proceeds. The Company anticipates that future sources of funding, if any, will therefore be costly and dilutive, if available at all. In view of the matters described in the preceding paragraphs, recoverability of the recorded asset amounts shown in the accompanying consolidated balance sheet assumes that (1) the effects of the COVID-19 crisis resume to pre-COVID-19 market conditions, (2) the Company will be able to establish a stabilized source of revenues, (3) obligations to the Company’s creditors are not accelerated, (4) the Company’s operating expenses remain at current levels and/or the Company is successful in restructuring and/or deferring ongoing obligations, (5) the Company is able to continue to produce products or obtain products under supply arrangements which are in compliance with current and future regulatory guidelines, (6) the Company is able to continue its research and development activities, particularly in regards to remaining compliant with the FDA and the safety and efficacy of its products, and (7) the Company obtains additional working capital to meet its contractual commitments and maintain the current level of Company operations through debt or equity sources. There is no assurance as to when the adverse impact to the United States and worldwide economies resulting from the COVID-19 outbreak will be eliminated, if at all, and whether any new or recurring pandemic outbreaks will occur again in the future causing similar or worse devastating impact to the United States and worldwide economies and our business. In addition, there is no assurance that the Company will be able to complete its revenue growth strategy, its expected required research and development activities or otherwise obtain sufficient working capital to cover ongoing cash requirements. Without sufficient cash reserves, the Company’s ability to pursue growth objectives will be adversely impacted. Furthermore, despite significant effort since July 2015, the Company has thus far been unsuccessful in achieving a stabilized source of revenues. As described above, the COVID-19 crisis has significantly impaired the Company and the overall Unites States and World economies. If revenues do not increase and stabilize, if the COVID-19 crisis is not satisfactorily managed and/or resolved or if additional funds cannot otherwise be raised, the Company might be required to seek other alternatives which could include the sale of assets, closure of operations and/or protection under the U.S. bankruptcy laws. As of January 31, 2021, based on the factors described above, the Company concluded that there was substantial doubt about its ability to continue to operate as a going concern for the 12 months following the issuance of these financial statements.

INVENTORIES

INVENTORIES	3 Months Ended
	Jan. 31, 2021
Inventory Disclosure [Abstract]
INVENTORIES	NOTE 4 – INVENTORIES January 31, October 31, Raw materials and supplies $ 23,321 $ 26,199 Finished goods 125,102 120,612 Total inventories $ 148,423 $ 146,811

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	3 Months Ended
	Jan. 31, 2021
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 5 - PROPERTY AND EQUIPMENT January 31, October 31, Computer equipment $ 8,653 $ 8,653 Finance lease equipment 239,595 239,595 Manufacturing equipment 217,694 171,430 465,942 419,678 Less: accumulated depreciation (66,636 ) (54,444 ) Total property and equipment, net $ 399,306 $ 365,234 During March 2019, the Company entered into a lease agreement for certain lab equipment in the amount of $239,595. Under the terms of the lease agreement, the Company is required to make 60 equal monthly payments of $4,513 plus applicable sales taxes. Under the Lease Agreement, the Company has the right to acquire all of the leased equipment for $1.00. As a result, the lease agreement is being accounted for as a finance lease obligation. The annual interest rate charged in connection with the lease is 4.5%. The leased equipment is being depreciated over their estimated useful lives of 15 years. Depreciation expense totaled $12,192 and $6,434 for the three months ended January 31, 2021 and 2020, respectively.

LEASE OBLIGATIONS

LEASE OBLIGATIONS	3 Months Ended
	Jan. 31, 2021
Leases [Abstract]
LEASE OBLIGATIONS	NOTE 6 – LEASE OBLIGATIONS 2019 Lab Facility: In connection with the Company’s decision to again operate a placental tissue bank processing laboratory in Miami, Florida, during February 2019, the Company entered into a renewable month to month lease agreement (“Miami Lab Lease”) for an approximately 450 square foot laboratory and a 100 square foot administrative office facility. Monthly lease payments are approximately $5,200 plus administrative fees and taxes. In connection with the Miami Lab Lease, the Company was required to post a security deposit of $6,332. During November 2020, the Company entered into an additional month to month lease agreement in the same facility as the Miami Lab Lease for an additional 390 square foot laboratory. Monthly lease payments are approximately $4,400 plus administrative fees and taxes. Finance Lease Obligations: During March 2019, the Company entered into a lease agreement for certain lab equipment in the amount of $239,595. Under the terms of the lease agreement, the Company is required to make 60 equal monthly payments of $4,513 plus applicable sales taxes. Under the Lease Agreement, the Company has the right to acquire all of the leased equipment for $1.00. As a result, the lease agreement is being accounted for as a finance lease obligation. The annual interest rate charged in connection with the lease is 4.5%. The leased equipment are being depreciated over their estimated useful lives of 15 years. Operating Lease Obligations: Administrative Office The Company’s corporate administrative offices are leased from MariLuna, LLC, a Florida limited liability company which is owned by Dr. Mitrani. During July 2020, the Company entered into an extension of the operating lease agreement. The lease term is for an additional 36 months beginning July 1, 2020, with a monthly rental rate of $3,500. On July 1, 2020, in connection with the adoption of ASC 842, the Company recorded a ROU asset and corresponding operating lease obligation of $117,659 (present value of the associated leased payments based on an assumed borrowing rate of 4.5%). Lease expense for the three months ended January 31, 2021 and 2020 was $9,350 and $8,475, respectively. Beginning October 1, 2020, the Company entered into a second lease agreement with Mariluna LLC for office space located in Aspen, CO. The lease expires on September 30, 2021 and does not provide for any renewal terms. Under the terms of the lease. The Company is required to make monthly rental payments of $6,500 and was required to provide a security deposit of $11,000 upon execution of the lease agreement.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Jan. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 7 – RELATED PARTY TRANSACTIONS On February 26, 2020, April 25, 2020 and June 29, 2020, Mr. Mitrani’s, Dr. Mitrani’s and Mr. Bothwell’s employment agreements were amended. See Note 12 for a more detailed description of the executive employment agreements and the respective amendments referred to above. During April 2020, June 2020, August 2020, September 2020 and February 2021, each of the current executives of the Company, Albert Mitrani, Dr. Mari Mitrani, Ian Bothwell and Dr. George Shapiro (“Current Executives”) were granted rights under the Management and Consultant Performance Plan (“MCPP”) to receive common stock of the Company based on the achievement of certain defined milestones. In addition, during June 2020, each of the current non-executive members of the Board were granted rights under the MCPP to receive common stock of the Company based on the achievement of certain defined milestones (see Note 10). The Company’s corporate administrative offices are leased from MariLuna, LLC, a Florida limited liability company which is owned by Dr. Mitrani. During July 2020, the term of the lease was been extended through June 2023. Beginning July 2020, the monthly rent increased from $2,900 to $3,500. The Company paid a security deposit of $5,000. Total rent expense for the three months ended January 31, 2021 and 2020 was $10,500 and $8,700, respectively. Beginning October 1, 2020, the Company entered into a second lease agreement with Mariluna LLC for office space located in Aspen, CO. The lease expires on September 30, 2021 and does not provide for any renewal terms. Under the terms of the lease. The Company is required to make monthly rental payments of $6,500 and was required to provide a security deposit of $11,000 upon execution of the lease agreement. Total rent expense for the three months ended January 31, 2021 was $19,500. In connection with Mr. Bothwell’s executive employment agreements, the Company agreed to reimburse Rover Advanced Technologies, LLC, a company owned and controlled by Mr. Bothwell for office rent and other direct expenses (phone, internet, copier and direct administrative fees, etc.) totaling $8,270 for the three months ended January 31, 2021. For the three months ended January 31, 2021, the Company sold a total of $333,760 of product to a management services organization (MSO) that provides administrative services and contracts for medical supplies for several medical practices, including $53,980 of products purchased from the Company that were attributable to the medical practice owned by one of our board of director members. The board of director member also has an indirect economic interest in the parent company that owns the MSO. For the three months ended January 31, 2020, the total amount of sales of products to customers related to our board of director members and/or employees of the Company totaled $10,400. At January 31, 2021, salary amounts owed to Albert Mitrani, Dr. Mari Mitrani and Ian Bothwell were $307,388, $295,555 and $725,340, respectively and consulting fees owed to Dr. George Shapiro were $75,396. On February 26, 2020, the Company agreed to enter into a consulting agreement with Dr. George Shapiro, the Company’s Chief Medical Officer (“CMO”) to provide ongoing services to the Company. The CMO will receive compensation of $82,250 annually, commencing March 1, 2020. The term of the consulting agreement is one year, with automatic renewals for annual periods thereafter unless prior written notice is provided by either party of the desire to terminate. During February 2021, the consulting arrangement was amended whereby the CMO’s accrued and unpaid consulting fees of $82,250 were fully satisfied though the issuance of 500,000 shares of newly issued common stock of the Company. Furthermore, until the CMO becomes a full-time employee of the Company and provided the CMO continues to serve in his current position, the CMO shall receive compensation equal to $27,000 per quarter beginning May 1, 2021, payable in cash or in stock (based on the average monthly trading price of the common stock during the applicable quarter) at the option of the Company. Effective December 21, 2020, the Company granted a bonus of $50,000 and 15,000,000 shares of common stock of the Company each to Mr. Mitrani, Dr. Mitrani and Mr. Bothwell and 1,000,000 shares of common stock of the Company each to Mr. Carbonara and Dr. Allen Meglin (see Note 10). On February 22, 2021, the Company sold 1,818,181 shares of common stock to Republic Asset Holdings LLC., a Company controlled by Michael Carbonara, a director of the Company, at $0.055 per share for an aggregate purchase price of $100,000 (see Note 10).

NOTES PAYABLE

NOTES PAYABLE	3 Months Ended
	Jan. 31, 2021
Debt Disclosure [Abstract]
Notes Payable	NOTE 8 - NOTES PAYABLE On June 20, 2018, the Company issued a total of $150,000 of convertible 6% debentures (“150,000 Debentures”) to an accredited investor. The principal amount of the $150,000 Debentures, plus accrued and unpaid interest through June 30, 2019 were payable on the 10 th th During October 2018, the Company issued a total of $70,000 of convertible 6% debentures (“70,000 Debentures”) to two accredited investors. The principal amount of the $70,000 Debentures, plus accrued and unpaid interest through September 30, 2019 were payable on the 10 th Credit Facility On September 19, 2019, the Company’s wholly owned subsidiary, General Surgical Florida, received $100,000 in connection with an unsecured line of credit (“Credit Facility”). The Credit Facility was fully repaid on November 2, 2020. Under the terms of the Credit Facility, the Company was required to make weekly payments averaging approximately $2,541 (payments totaling $132,160). The effective annual interest rate was approximately 45.67%. Proceeds received from the Credit Facility were used for working capital purposes. Mr. Iglesias, who at the time was the Company’s Chief Executive Officer, provided a personal guaranty in connection with amounts required to paid under the Credit Facility.

IRS PENALTIES

IRS PENALTIES	3 Months Ended
	Jan. 31, 2021
Irs Penalties
IRS PENALTIES	NOTE 9 — IRS PENALTIES The Company’s income tax returns for the periods since inception through the tax year ended October 31, 2015 were not filed with the Internal Revenue Service (“IRS”) until August 2017 (“Delinquent Filed Returns”). The Company’s income tax returns for the tax year ended October 31, 2016 were filed with the IRS during December 2017. In connection with the Delinquent Filed Returns, during the period September 2017 through October 2017, the Company received notices that it was being assessed approximately $90,000 of penalties, plus interest (“IRS Penalties”), in connection with the late filing certain information returns that were included as part of the Delinquent Filed Returns. In connection with the notices, the IRS indicated its intent to levy property of the Company if the IRS penalties were not paid as required. During January 2018, the Company requested from the IRS an abatement of the IRS penalties based on reasonable cause. During April 2018, the IRS notified the Company that the IRS penalties for the tax year ended 2011 of $20,000, plus interest, were abated and the request for abatement for the IRS penalties for the tax years ended 2012 – 2015 were denied. The Company is currently appealing the initial determination by the IRS to exclude the IRS penalties for the tax years 2012-2015 in its consideration of abatement. During the period that the appeal is being reviewed and a determination is made by the IRS, the IRS has agreed to put a hold on taking any levy action against the Company for the remaining amounts of the IRS Penalties that are still outstanding. In connection with the notices, the Company has accrued $70,000 of accrued tax penalties on the balance sheet as of January 31, 2021 and October 31, 2020.

CAPITAL STOCK

CAPITAL STOCK	3 Months Ended
	Jan. 31, 2021
Equity [Abstract]
Capital Stock	NOTE 10 – CAPITAL STOCK Preferred Stock The Company is authorized to issue 10,000,000 shares of $0.001 par value preferred stock in one or more designated series, each of which shall be so designated as to distinguish the shares of each series of preferred stock from the shares of all other series and classes. The Company’s board of directors is authorized, without stockholders’ approval, within any limitations prescribed by law and the Company’s Articles of Incorporation, to fix and determine the designations, rights, qualifications, preferences, limitations and terms of the shares of any series of preferred stock. Issued Shares As of January 31, 2021, there were no designations of Preferred Stock authorized or outstanding. Common Stock On December 21, 2020 and January 4, 2021, pursuant to the Nevada Revised Statutes and the Bylaws of the Company, the Board of Directors of the Company and the stockholders having the voting equivalency of 53.55% of the outstanding capital stock, respectively, approved the filing of an amendment to the Articles of Incorporation of the Company to increase the authorized amount of common stock from 1,500,000,000 to 2,500,000,000, without changing the par value of the common stock or authorized number and par value of “blank check” Preferred Stock. On January 19, 2021, the Company filed a Definitive 14C with the SEC regarding the corporate action. On February 10, 2021, the Company filed a Certificate of Amendment to the Company’s Articles of Incorporation with the Secretary of State of Nevada to effectuate the corporate action on February 9, 2021. Issuances of Common Stock - Sales: During November 2020, the Company sold 800,000 shares of common stock to an “accredited investor”, at $0.05 per share, for an aggregate purchase price of $40,000. The proceeds were used for working capital. During February 2021, the Company sold an aggregate of 12,340,910 shares of common stock to five “accredited investors”, at prices ranging from $0.05 per share to $0.06 per share for an aggregate purchase price of $665,000. The proceeds were used for working capital. On February 22, 2021, the Company sold 1,818,181 shares of common stock to Republic Asset Holdings LLC., a Company controlled by Michael Carbonara, a director of the Company, at $0.055 per share for an aggregate purchase price of $100,000. The proceeds were used for working capital. The sales price was at a discount to the trading price of $0.086 as of the effective date of the transaction, resulting in additional stock-based compensation expense of $56,364, which has been recorded during the quarter ended April 30, 2021. Issuances of Common Stock – Stock Compensation: During November 2020, the Company entered into an additional consulting agreement with a third party to provide consulting services in connection with the development of international research and development, sales and distribution and financing opportunities for a period of six months. As consideration for agreeing to provide the consulting services to the Company, the Company issued the consultant 2,000,000 shares of fully vested unregistered common stock valued at $0.145 per share, the closing price of the common stock of the Company on the effective date of the agreement. The Company recorded $290,000 of stock-based compensation expense during the three months ended January 31, 2021. During November 2020, in consideration for agreeing to provide medical consulting and advisory services to the Company, the Board approved the issuance to one individual an aggregate of 250,000 shares of unregistered common stock valued at $0.145 per share, the closing price of the common stock of the Company on the respective grant dates. The Company recorded $36,225 of stock-based compensation expense based on the grant date fair value of these shares during the quarter ended January 31, 2021. During December 2020, the Board approved the bonus of 47,675,000 shares of newly issued common stock to executive management (consisting of Mr. Mitrani, Dr. Mitrani and Mr. Bothwell) totaling 45,000,000 shares; non-executive Board members (consisting of Mr. Carbonara and Dr. Meglin) totaling 2,000,000 shares; administrative staff totaling 550,000; and to several medical advisors totaling 125,000 shares. The Company recorded a total of $5,721,000 of stock-based compensation expense based on the grant date fair value of these shares during the quarter ended January 31, 2021. During December 2020, January 2021 and February 2021, the Company issued 25,000, 240,000 and 50,000 shares of unregistered common stock, respectively, valued at prices ranging from $0.35 to $0.17 per share, the closing price of the common stock of the Company on the respective grant dates. The Company recorded $14,480 of stock-based compensation expense during the quarter ended January 31, 2021 and will record $7,875 of stock-based compensation expense during the quarter ended April 30, 2021 based on the grant date fair value of these shares. During February 2021, the consulting arrangement was amended whereby the CMO’s accrued and unpaid consulting fees of $82,250 were fully satisfied though the issuance of 500,000 shares of newly issued common stock of the Company. Furthermore, until the CMO becomes a full-time employee of the Company and provided the CMO continues to serve in his current position, the CMO shall receive compensation equal to $27,000 per quarter beginning May 1, 2021, payable in cash or in stock (based on the average monthly trading price of the common stock during the applicable quarter) at the option of the Company. During February 2021, the Company entered into a consulting agreement with a third party to provide consulting services for a one-year period. As consideration for agreeing to provide consulting services to the Company, the Company agreed to issue the consultant 500,000 shares of unregistered common stock upon completion of the three-month anniversary of the agreement. In addition, the Company has agreed to provide an additional 250,000 shares of newly issued common stock for each celebrity and/or athlete which the consultant arranges to provide marketing services to the Company and that is responsible for bringing a minimum of $75,000 of monthly revenues in connection with sales of the Company’s products. The shares issued were valued at $0.08 per share, the closing price of the common stock of the Company on the effective date of the agreement. Management and Consultants Performance Stock Plan On April 25, 2020, the Company approved the adoption of the Management and Consultants Performance Stock Plan (“MCPP”) providing for the grant to current senior executive members of management and third-party consultants of an aggregate of approximately 205,000,000 shares of common stock of the Company (“Shares”) based on the achievement of certain defined operational performance milestones (“Milestones”). On June 29, 2020, the Board amended the MCPP, providing for the additional grant of common stock of the Company to the current senior executive members of management and the current non-executive members of the Board based on the Company completing any transaction occurring while employed and/or serving as a member of the Board, respectively, that results in a change in control of the Company or any sale of substantially all the assets of the Company (“Transaction”) which upon after giving effect to such issuance of shares below, corresponds to a minimum pre-Transaction fully diluted price per share of the Company’s common stock in the amounts indicated below. Pre-Transaction Executive Bonus Non-executive $ 0.22 40,000,000 2,000,000 $ 0.34 60,000,000 3,000,000 $ 0.45 80,000,000 4,000,000 $ 0.54 100,000,000 5,000,000 (a) proforma for issuance of all shares to be issued pursuant to the MCPP and other in the money contingent share issuances (b) per each executive consisting of Albert Mitrani, Dr. Mari Mitrani, Ian Bothwell, and Dr. George Shapiro (c) per each non-executive Board member consisting of Dr. Allen Meglin and Michael Carbonara On August 14, 2020, the Board amended the MCPP, providing for the additional grant of common stock of the Company to each Dr. Maria I. Mitrani and Ian Bothwell based on the Company obtaining aggregate gross fundings (grants for research and development and clinical trials, purchase contracts for Company products, debt and/or equity financings) or other financial awards during the term of employment with the Company based on the amounts indicated below: Aggregate Funding Amount Shares From To $ 2,500,000 $ 5,000,000 5,000,000 $ 5,000,001 $ 10,000,000 10,000,000 $ 10,000,001 $ 30,000,000 30,000,000 On September 23, 2020, the Board amended the MCPP, providing for the grant of common stock of the Company of 15.0 million, 7.5 million and 15.0 million shares of common stock of the Company, respectively, to each Albert Mitrani, Dr. Maria I. Mitrani and Ian Bothwell upon such time that the Company’s common stock trades above $0.25 per share, $0.50 per share and $0.75 per share, respectively, for 30 consecutive trading days subsequent to March 31, 2021 and provided such milestone occurs during the term of employment with the Company. In addition, each of the current executives were entitled to receive an additional 7 million shares, which when combined with all previous IND and/or eIND’s Milestones previously issued under the MCPP of 43 million shares, represents the total of all incentive shares to be issued to each executive in connection with the combined thirteen IND’s and/or eIND’s Milestones achieved through September 23, 2020. In the future, each of the current executives shall be entitled to receive 5 million shares as a performance incentive for each IND and/or “Expanded Access” approval (and excluding all eIND’s) received by the Company that involve more than 15 patients and provided such milestone occurs during the term of employment with the Company. On February 10, 2021, the Board amended the MCPP, providing for the grant of common stock of the Company of 5 million shares for each Phase II clinical trial completed, 5 million shares for each Phase III clinical trial approved and initiated (deemed to be upon the time the first patient is enrolled) and 10.0 million shares for each Phase III clinical trial fully enrolled. In addition, the CMO’s portion of a designated grant for an achievement of any applicable Milestone subsequent to September 23, 2020 was reduced to 30% until the time that the CMO becomes a full-time employee of the Company. Pursuant to the MCPP, a total of 326,000,000 shares have been issued and as described above, additional shares are authorized to be issued under the MCPP subject to the achievement of the defined contingent performance based milestones described above and provided the milestones are achieved while the individual is employed and/or serving as a member of the Board: MCPP Shares Name Awarded Albert Mitrani 75,000,000 Ian Bothwell 75,000,000 Dr. Maria I. Mitrani 75,000,000 Dr. George Shapiro 68,000,000 Consultants 33,000,000 Total 326,000,000 The Company will record stock-based compensation expense in connection with any MCPP Shares that are actually awarded based on the fair value as of the initial grant date that the respective milestone for the MCPP Shares were approved. For the MCPP Shares approved on April 25, 2020, June 29, 2020, August 14, 2020, September 23, 2020, and February 10, 2021, the closing price of the common stock of the Company was $0.027, $0.056, $0.128, $0.28 and 0.108, respectively. In connection with the MCPP Shares that have been awarded to date, all such shares were issued in connection with the MCPP Shares approved on April 25, 2020 and accordingly were valued $0.027 per share, the closing price of the common stock of the Company on the date that those respective MCPP Shares were approved. During the quarter ended January 31, 2021 and on February 10, 2021, a total of 16,500,000 and 16,500,000 shares, respectively, were issued in connection with certain Milestones achieved. The Company recorded a total of $445,500 of stock-based compensation expense during the quarter ended January 31, 2021 and will record $445,500 of stock-based compensation expense during the quarter ended April 30, 2021, based on the fair value of the actual MCPP Shares awarded during each of those respective periods.

WARRANTS

WARRANTS	3 Months Ended
	Jan. 31, 2021
Warrants
Warrants	NOTE 11 – WARRANTS A summary of warrant activity for the three months ended January 31, 2021 and 2020 are presented below. Number of Weighted-average Remaining Aggregate Outstanding at October 31, 2020 9,500,000 $ 0.03 7.90 $ 1,268,000 Granted — $ — — $ — Exercised — $ — — $ — Expired/Forfeited — $ — — $ — Outstanding and exercisable at January 31, 2021 9,500,000 $ 0.03 7.65 $ 546,000 Number of Weighted-average Remaining Aggregate Outstanding at October 31, 2019 4,529,371 $ 0.20 0.30 $ — Granted — $ — — $ — Exercised — $ — — $ — Expired/Forfeited (1,271,428 ) $ 0.15 — $ — Outstanding and exercisable at January 31, 2020 3,257,943 $ 0.22 0.08 $ —

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Jan. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 12 – COMMITMENTS AND CONTINGENCIES The description of Mr. Mitrani’s, Dr. Mitrani’s and Mr. Bothwell’s executive employment agreements executed in April 2018 (collectively referred to as the April 2018 Executive Employment Agreements) are summarized below: April 2018 Executive Employment Agreements General Pursuant to Albert Mitrani’s April 2018 Executive Employment Agreement, Mr. Mitrani serves as the Company’s President and Chief Operating Officer. Mr. Mitrani’s base annual salary is $162,500, which shall accrue commencing on the Effective Date and shall be payable in equal semi-monthly installments, commencing May 1, 2018, in arrears. The base salary shall be reviewed at least annually by the Board and the Board may, but shall not be required to, increase the base salary during the Employment Term. Mr. Mitrani is also entitled to a commission on all sales attributable to him (i.e., excluding existing customers of the Company at the time of the Reorganization) at the rate of five percent (5%) of the “Net Sales” as defined in the agreement and an expense allowance of $5,000 per month. Pursuant to Ian Bothwell’s April 2018 Executive Employment Agreement, Mr. Bothwell continues to serve as the Company’s Chief Financial Officer. Mr. Bothwell’s base annual salary is $162,500, which shall accrue commencing on the Effective Date and shall be payable in equal semi-monthly installments, commencing May 1, 2018, in arrears. The base salary shall be reviewed at least annually by the Board and the Board may, but shall not be required to, increase the base salary during the Employment Term. Mr. Bothwell has not been paid salary since July 2018. Pursuant to Dr. Maria I. Mitrani’s April 2018 Executive Employment Agreement, Dr. Mitrani continues to serve as the Company’s Chief Science Officer. Dr. Mitrani’s base annual salary is $162,500, which shall accrue commencing on the Effective Date and shall be payable in equal semi-monthly installments, commencing May 1, 2018, in arrears. The base salary shall be reviewed at least annually by the Board and the Board may, but shall not be required to, increase the base salary during the Employment Term. Term The term of each of the April 2018 Executive Employment Agreements commences as of the Effective Date and continues until December 31, 2020 (Mr. Bothwell) or December 31, 2023 (Mr. Mitrani and Dr. Mitrani) (“Initial Term”), unless terminated earlier pursuant to the terms of the April 2018 Executive Employment Agreement; provided that Unpaid Advances The Company was required to repay the unpaid advances subsequent to December 31, 2017, and the unreimbursed expenses incurred subsequent to December 31, 2017, on May 15, 2018. Such payments were not made as required. Fringe Benefits and Perquisites During the Employment Term, each Executive shall be entitled to fringe benefits and perquisites consistent with the practices of the Company, and to the extent the Company provides similar benefits or perquisites (or both) to similarly situated executives of the Company. Termination The Company may terminate the April 2018 Executive Employment Agreement at any time for good cause, as defined in the April 2018 Executive Employment Agreement, including, the Executive’s death, disability, Executive’s willful and intentional failure or refusal to follow reasonable instructions of the Company’s Board of Directors, reasonable and material policies, standards and regulations of the Company’s Board of Directors or management. Amendments To The April 2018 Executive Employment Agreements February 26, 2020 Amendment 1. On February 26, 2020, the Company agreed to modify the employment agreement of Mr. Ian T. Bothwell, the Company’s Chief Financial Officer to provide Mr. Bothwell with: a) an extension to his employment agreement dated April 13, 2018 from December 2020 to December 2023 consistent with other executives of the Company; and b) and a one-time bonus in the form of a fully vested cashless warrant to purchase 7,500,000 shares of common stock of the Company, exercisable for ten years at an exercise price of $0.28 per share, the closing price of the common stock on the date of the grant. 2. On February 26, 2020, pursuant to the respective employment agreements with each of the Company’s executive officers, the Board granted each of Mr. Albert Mitrani, Dr. Maria Mitrani and Mr. Ian Bothwell a cash bonus of $37,500 for the calendar year ended December 31, 2019. April 25, 2020 Amendment On April 25, 2020, the Company agreed to amend and revise the each of Albert Mitrani, Ian Bothwell and Dr. Maria I. Mitrani, (individually each of A. Mitrani, Bothwell and Dr. Mitrani are referred to as an “Executive” and collectively the “Executives”) April 2018 Executive Employment Agreements. The primary amended terms associated with the agreements for each Executive were substantially similar and consisted of the following: Term: An extension to the term of the employment agreements dated April 13, 2018 from December 31, 2023 to December 31, 2025. Base Salary: An increase in base annual salary from $162,500 to $300,000. The amended salary amount of $300,000 shall be retroactively adjusted to commence as of January 1, 2019. The increased annual salary of $137,500 (“Incremental Salary”) over the prior annual salary amount of $162,500 (“Original Base Salary”) shall only be paid only upon there being sufficient available cash. Beginning July 1, 2020, at the sole option of the Executive, any portion of unpaid Original Base Salary for periods after January 1, 2020, including unpaid bonus salary, may be converted by Executive into common stock at a conversion rate equal to the average trading price during the month in which the accrued salary pertains. For any unpaid Original Base Salary that existed prior to January 1, 2020, including unpaid bonus salary, the amounts may be converted at a conversion price using the closing trading price of the stock on the last trading day in December 2019. Beginning December 1, 2020, at the sole option of the Executive, all unpaid Incremental Salary for periods after January 1, 2020 may be converted by the Executive into common stock at a conversion rate equal to the average trading price during the month in which the accrued salary pertains. For any unpaid Incremental Salary that existed prior to January 1, 2020, the amounts may be converted at a conversion price using the closing trading price of the stock on the last trading day in December 2019. Until such time as the Executive elects to convert, the accrued and unpaid salary, including Original Base Salary and Incremental Salary shall remain an obligation of the Company. Severance Provisions: 1. Company termination without cause, Executive for good reason: a) All existing accrued obligations existing at time of termination shall be paid to Executive. b) Any unvested equity grants in favor of Executive shall immediately become fully vested and any pending grants pursuant to the MCPP eligible to be issued to Executive shall be granted to Executive, regardless of whether the associated milestone were achieved prior to termination, c) Executive shall be entitled to a cash payment equal to his unpaid base salary for the remaining term in effect at time of the time of the termination or an amount equal to four times (4x’s) the base salary in effect at the time of termination, whichever is greater, d) Executive shall be entitled to a cash payment equal to his 200% of the prior year’s cash or stock bonus (excluding any stock grants received pursuant to the MCPP). 2. Change In Control: In the event of a Change in Control and the Executive’s employment agreement is not extended for period of five years from the date of the Change in Control with all other terms and conditions of the agreement remaining the same, then the Executive may terminate the agreement for good reason and all respective severance terms as provided for a termination by Executive for good reason described in clause 1 above shall be provided to Executive. 3. Executive termination due to disability, death, or non-renewal by Company: a) All existing accrued obligations existing at time of termination shall be paid to Executive. b) Any unvested equity grants in favor of Executive shall immediately become fully vested and any pending grants pursuant to the MCPP eligible to be issued to Executive shall be granted to Executive, regardless of whether the associated milestone were achieved prior to termination. c) Executive shall be entitled to a cash payment equal to 299% of Executive’s base salary in effect at the time of termination, plus a gross up amount to cover Executive’s tax liability associated with such payment. d) 200% of the prior years cash or stock bonus (excluding MCPP performance stock grants). June 29, 2020 Amendment On June 29, 2020, the board of directors of the Company (“Board”) agreed to further amend and revise the April 2018 Executive Employment Agreements for each of Executives. The primary amended terms associated with the agreements for each Executive were substantially similar and consisted of the following: Base Salary: An increase in the Executives annual base annual salary upon such time that the Company achieves monthly revenues in the amounts provided below, provided such monthly revenue increase occurs for four consecutive months. Upon the achievement of the defined salary milestone, the salary adjustment will be retroactive to the first month in which the salary threshold was met. Any adjustment pursuant to this provision shall not be reduced for any future reduction in revenues that may occur. Monthly Revenues Base Salary $ 1.00 $ 130,000 $ 1.50 $ 200,000 $ 2.00 $ 275,000 $ 3.50 $ 630,000 $ 5.00 $ 900,000 Sales Executives On January 6, 2020, the Company entered into employment agreements with two individuals (“Sales Executives”), each to serve as a Vice President – Global Sales and Marketing. The terms of each Sales Executive employment agreement are identical (“VP Agreements”). The initial term of the VP agreements are for three years and provide for automatic annual renewals thereafter, unless either party provides 90-day written notice prior to expiration of the then current term. The VP Agreements may also be terminated by the Company beginning June 30, 2020 in the event the Sales Executive fails to meet certain defined minimum revenue growth milestones. The Sales Executives will receive compensation in the form of monthly salary of $18,000 and a quarterly override during the calendar year 2020 based on revenues earned by the Company during each quarterly period that exceed $600,000 (“Override Threshold”) beginning for the quarter ended June 30, 2020. The VP Agreements also require the Sales Executives and the Company to mutually agree on the Override Threshold for calendar years 2021 and 2022, which has yet to be agreed to. The VP Agreements also provide the Sales Executives with the right for each to receive an additional 750,000 shares of common stock at the end of each quarterly anniversary of the VP Agreements throughout the Initial Term (maximum 9,000,000 shares) (“Performance Shares”), provided that the VP Agreements remain in effect during the applicable quarterly period. The vesting of the Performance Shares may also be accelerated based on achievement of certain revenue milestones. During the quarter ended January 31, 2021, a total of 2,700,000 of Performance shares vested in connection with the VP Agreements resulting in stock-based compensation expense of $94,500. Consultant Agreements Effective March 30, 2020 (the “Effective Date”), the Company entered into a consulting agreement (“Agreement”) with Assure Immune L.L.C. (the “Consultant”) for an initial term of one year (the “Initial Term”) with automatic renewals for two (2) additional annual periods (each a “Renewal Term,” and together with the “Initial Term,” the “Term”), unless written notice is provided by either party at least 45 days prior to the applicable termination date. Neither party provided written notice within the specified deadlines to terminate upon expiration of the Initial Term and as a result the Term has been extended to March 30, 2022. Under the Agreement, the Consultant will provide the Company during the Term with expertise, experience, advice and direction associated with the critical functional executive level roles of the Company as it relates to the oversight and management of the Company’s regulatory, research and development and laboratory operations, consistent with the Company’s corporate mission and strategies and subject to the resource limitations of the Company. In connection with the Agreement, the Consultants will receive monthly fees of $30,000 during the Initial Term and monthly consulting fees of $35,000 during the first Renewal Term and $40,000 during the second Renewal Terms, if any. In addition. the Company agreed to issue to the Consultant or its designees 12,000,000 shares of common stock of the Company (“Shares”), 50% of which Shares vest as of the Effective Date and balance of which Shares vest upon the six-month anniversary of the Effective Date. The Agreement also provides that upon the commencement of each Renewal Term, if any, the Consultant will receive up to 6,000,000 additional Shares, 50% of which Shares will vest on the commencement date of the Renewal Term and the balance of which additional Shares will vest on the six (6) month anniversary of such date. In connection with the Agreement, the Consultant (and its principals ) During October 2020, the Company entered into a consulting agreement with a third party to provide consulting services in connection with the development of international research and development, sales and distribution and investment opportunities. As consideration for agreeing to provide the consulting services to the Company, the Company has agreed to pay the consultants a minimum of $12,500 per month for the first three months of the agreement and to issue up to 5,000,000 shares of restricted common stock (valued at $0.175 per share, the closing price of the common stock of the Company on the grant date), based on successful performance of defined milestones. The agreement may be terminated after the third month anniversary of the agreement with or without cause. The Company will record up to $875,000 of stock-based compensation expense at the time that any shares actually become vested as a result of achievement of the defined milestones. Preparation of IRB, Pre-IND, IND Protocols for Clinical Applications and Clinical Trial Initiation and Monitoring: In connection with the Company’s ongoing research and development efforts and the Company’s efforts to meet compliance with current and anticipated United States Food and Drug Administration (“FDA”) regulations expected to be enforced beginning in May 2021 pertaining to marketing traditional biologics and human cells, tissues and cellular and tissue based products that fall under Section 351 of the Public Health Services Act (“HCT/Ps”), the Company has applied for and received Investigation New Drug (“IND”) approval from the FDA to commence clinical trials in connection with the use of the Company’s products and related treatment protocols for specific indications. The ability to successfully complete the above efforts will be dependent on the Company’s ability to timely fund the required payments and complete the applicable clinical trials, which is subject to available working capital generated from operations, financing arrangements with the third-party vendors involved in the studies and/or from additional debt and/or equity financings as well as ultimate approval from the FDA. During November 2020, the Company entered into an agreement with a third-party contract research organization (“CRO”) to provide ongoing clinical research services, clinical research professionals and contract clinical, technical and other related services in connection with a planned future clinical trial. In connection with the CRO agreement, the Company is obligated to make payments of approximately $777,714 plus pass through costs and other third-party direct costs during the term of clinical trial expected to run until September 2021. In connection with the agreement, the Company is obligated to pay in accordance with defined completed milestones, beginning with approximately $195,524 upon work order execution. During January 2021, the Company entered into an additional agreement with the CRO to provide ongoing clinical research services, clinical research professionals and contract clinical, technical and other related services in connection with a planned future clinical trial. In connection with the CRO agreement, the Company is obligated to payments of approximately $476,943 plus pass through costs and other third-party direct costs during the term of clinical trial expected to run until August 2021. In connection with the agreement, the Company is obligated to pay in accordance with defined completed milestones, beginning with approximately $147,363 upon work order execution. For the three months ended January 31, 2021, the Company incurred approximately $432,000 of expenses in connection with the above CRO agreements of which $432,000 was outstanding to the CRO at January 31, 2021. Contingent Convertible Obligations Into Equity Securities Obligations Due Under Executive Employment Agreements Beginning July 1, 2020, at the sole option of the Executive, any portion of unpaid Original Base Salary for periods after January 1, 2020, including unpaid bonus salary, may be converted by Executive into common stock at a conversion rate equal to the average trading price during the month in which the accrued salary pertains. For any unpaid Original Base Salary that existed prior to January 1, 2020, including unpaid bonus salary, the amounts may be converted at a conversion price using the closing trading price of the stock on the last trading day in December 2019. Beginning December 1, 2020, at the sole option of the Executive, all unpaid Incremental Salary for periods after January 1, 2020 may be converted by the Executive into common stock at a conversion rate equal to the average trading price during the month in which the accrued salary pertains. For any unpaid Incremental Salary that existed prior to January 1, 2020, the amounts may be converted at a conversion price using the closing trading price of the stock on the last trading day in December 2019. None of the Executives have yet to elect to convert any portion of their unpaid Original Base Salary. As of January 31, 2021, there was approximately $721,415 of unpaid Original Base Salary and Incremental Salary related to the period prior to December 31, 2019 and $552,817 of unpaid Original Base Salary and Incremental Salary related to the period January 1, 2020 through January 31, 2021, that could be converted in the future into approximately 33,719,900 shares of common stock .

SEGMENT INFORMATION

SEGMENT INFORMATION	3 Months Ended
	Jan. 31, 2021
Segment Reporting [Abstract]
Segment Information	NOTE 13 - SEGMENT INFORMATION The Company has only one operating segment.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Jan. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The unaudited consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities Exchange Commission, although we believe that the disclosures made are adequate to make the information not misleading. These unaudited consolidated financial statements should be read in conjunction with our Annual Report on Form 10-K for the year ended October 31, 2020 filed with the Securities and Exchange Commission.
Concentrations of Credit Risk	Concentrations of Credit Risk The balance sheet items that potentially subject us to concentrations of credit risk are primarily cash and cash equivalents. Balances in accounts are insured up to Federal Deposit Insurance Corporation (“FDIC”) limits of $250,000 per institution. At January 31, 2021, the Company did not hold cash balances in any financial institution in excess of FDIC insurance coverage limits.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles of the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Management bases its estimates on historical experience and on other assumptions considered to be reasonable under the circumstances. However, actual results may differ from the estimates.
Cash Equivalents	Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents.
Accounts Receivable	Accounts Receivable Accounts receivable are recorded at fair value on the date revenue is recognized. The Company provides allowances for doubtful accounts for estimated losses resulting from the inability of its customers to pay their obligation. If the financial condition of the Company's customers were to deteriorate, resulting in an impairment of their ability to repay, additional allowances may be required. The Company provides for potential uncollectible accounts receivable based on specific customer identification and historical collection experience adjusted for existing market conditions. The policy for determining past due status is based on the contractual payment terms of each customer, which are generally net 30 or net 60 days. Once collection efforts by the Company and its collection agency are exhausted, the determination for charging off uncollectible receivables is made. For the three months ended January 31, 2021 and 2020, the Company did not record any bad debt expense.
Inventory	Inventory Inventory is stated at the lower of cost or net realizable value using the average cost method. The Company provides reserves for potential excess, dated or obsolete inventories based on an analysis of forecasted demand compared to quantities on hand and any firm purchase orders, as well as product shelf life. At January 31, 2021, the Company determined that there were not any reserves required in connection with our finished goods.
Property and Equipment	Property and Equipment Property and equipment are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives of property and equipment range from 3 to 15 years. Upon sale or retirement, the cost and related accumulated depreciation and amortization are eliminated from their respective accounts, and the resulting gain or loss is included in results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred.
Revenue Recognition	Revenue Recognition The Company follows the guidance of FASB Accounting Standards Update (“ASU”) Topic 606 “Revenue from Contracts with Customers” which requires the Company to recognize revenue in amounts that reflect the prorata completion of the performance obligations of the Company required under the contracts. The Company applied the new standard using a modified retrospective approach. The Company recognizes revenue only when it transfers control of a promised good or service to a customer in an amount that reflects the consideration it expects to receive in exchange for the good or service. Our performance obligations are satisfied and control is transferred at a point-in-time, which is typically when the transfer and title to the product sold has taken place and there is evidence of our customer’s satisfactory acceptance of the product shipment or delivery.
Net Income (Loss) Per Common Share	Net Income (Loss) Per Common Share Basic income (loss) per common share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted average number of shares adjusted for any potentially dilutive debt or equity. At January 31, 2021, the Company had 9,500,000 common shares issuable upon the exercise of warrants that were not included in the computation of dilutive loss per share because their inclusion is anti-dilutive for the three months ended January 31, 2021. At January 31, 2020, the Company had 3,257,943 common shares issuable upon the exercise of warrants that were not included in the computation of dilutive loss per share because their inclusion is anti-dilutive for the three months ended January 31, 2020.
Stock-Based Compensation	Stock-Based Compensation All share-based payments to employees, including grants of employee stock options, are recognized in the financial statements based on their fair values. Stock options and warrants issued to consultants and other non-employees as compensation for services provided to the Company are accounted for based upon the estimated fair value of the option or warrant.
Research and Development Costs	Research and Development Costs Research and development costs consist of direct and indirect costs associated with the development of the Company’s technologies. These costs are expensed as incurred. Our research and development expenses were approximately $662,000 and $72,000 for the three months ended January 31, 2021 and 2020, respectively. The research and development costs primarily relate to the filing and approval of IND applications and the performance of clinical trials.
Income Taxes	Income Taxes The Company is required to file a consolidated tax return that includes all of its subsidiaries. Provisions for income taxes are based on taxes payable or refundable for the current year taxable income for federal and state income tax reporting purposes and deferred income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss carryforwards. Deferred income tax expense represents the change during the period in the deferred tax assets and deferred tax liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of the operations in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with FASB Topic 740 – Income Taxes. This pronouncement prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. The interpretation also provides guidance on recognition, derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. For the three months ended January 31, 2021 and 2020 the Company incurred operating losses, and therefore, there was not any income tax expense amount recorded during that period. There is a full valuation allowance established for the tax benefit associated with the net losses for the three months ended January 31, 2021 and 2020.
Valuation of Derivatives	Valuation of Derivatives The Company evaluates its convertible instruments, options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under ASC Topic 815, “Derivatives and Hedging.” The result of this accounting treatment is that the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income (expense). Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Equity instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815 are reclassified to liabilities at the fair value of the instrument on the reclassification date.
Sequencing	Sequencing The Company has adopted a sequencing policy whereby, in the event that reclassification of contracts from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of shares. The Company currently has 2,500,000,000 authorized shares of common stock of which 1,041,341,874 shares are issued and outstanding. The Company expects that it will continue to issue common stock in the future in connection with debt and/or equity financings, transactions with third parties, performance incentives and as compensation to its employees. Currently the amount of authorized shares is sufficient to provide for the additional shares that the Company may be contingently obligated to issue under existing arrangements.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company includes fair value information in the notes to financial statements when the fair value of its financial instruments is different from the book value. When the book value approximates fair value, no additional disclosure is made. The Company follows FASB ASC 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value and enhances disclosures about fair value measurements. It defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company’s financial instruments consist of cash and cash equivalents, accounts payable, accrued liabilities and convertible debt. The estimated fair value of cash, accounts payable and accrued liabilities approximate their carrying amounts due to the short-term nature of these instruments. The Company follows the provisions of ASC 820 with respect to its financial instruments. As required by ASC 820, assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. Level one Level two Level three The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. The Company did not have any convertible instruments outstanding at January 31, 2021 and October 31, 2020 that qualify as derivatives.
Operating and Finance Lease Obligations	Operating and Finance Lease Obligations Effective November 1, 2019, the Company adopted Accounting Standards Update (ASU) No. 2016-02 (Topic 842) (“ASC 842”), that requires organizations that lease assets to recognize assets and liabilities on the balance sheet and provide updated disclosures related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. The Company adopted the new standard using a modified retrospective approach. The modified retrospective approach included a number of optional practical expedients on leases that commenced before the effective date of ASC 842, including continuing to account for leases that commenced before the effective date in accordance with previous guidance, unless the lease is modified. Under the provisions of ASC 842, the Company is required to recognize a right of use (“ROU”) asset and corresponding lease liability for all operating leases upon commencement of the lease. The Company’s policy is to treat operating leases that have a term of one year or less at lease commencement date and do not include a purchase option that is reasonably certain of exercise, consistent with the lease recognition approach as previously outlined under ASC 840. In addition, month to month leases which do not involve additional financial commitments on the part of the Company are also treated consistent with the lease recognition approach as previously outlined under ASC 840. The Company has established a capitalization threshold of $15,000 in determining whether any future operating leases will be capitalized.
Subsequent Events	Subsequent Events The Company has evaluated subsequent events that occurred after January 31, 2021 through the financial statement issuance date for subsequent event disclosure consideration.

INVENTORIES (Tables)

INVENTORIES (Tables)	3 Months Ended
	Jan. 31, 2021
Inventory Disclosure [Abstract]
Schedule of Inventories	January 31, October 31, Raw materials and supplies $ 23,321 $ 26,199 Finished goods 125,102 120,612 Total inventories $ 148,423 $ 146,811

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	3 Months Ended
	Jan. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	January 31, October 31, Computer equipment $ 8,653 $ 8,653 Finance lease equipment 239,595 239,595 Manufacturing equipment 217,694 171,430 465,942 419,678 Less: accumulated depreciation (66,636 ) (54,444 ) Total property and equipment, net $ 399,306 $ 365,234

CAPITAL STOCK (Tables)

CAPITAL STOCK (Tables)	3 Months Ended
	Jan. 31, 2021
Equity [Abstract]
Schedule of minimum pre-Transaction price per share	On June 29, 2020, the Board amended the MCPP, providing for the additional grant of common stock of the Company to the current senior executive members of management and the current non-executive members of the Board based on the Company completing any transaction occurring while employed and/or serving as a member of the Board, respectively, that results in a change in control of the Company or any sale of substantially all the assets of the Company (“Transaction”) which upon after giving effect to such issuance of shares below, corresponds to a minimum pre-Transaction fully diluted price per share of the Company’s common stock in the amounts indicated below. Pre-Transaction Executive Bonus Non-executive $ 0.22 40,000,000 2,000,000 $ 0.34 60,000,000 3,000,000 $ 0.45 80,000,000 4,000,000 $ 0.54 100,000,000 5,000,000 (a) proforma for issuance of all shares to be issued pursuant to the MCPP and other in the money contingent share issuances (b) per each executive consisting of Albert Mitrani, Dr. Mari Mitrani, Ian Bothwell, and Dr. George Shapiro (c) per each non-executive Board member consisting of Dr. Allen Meglin and Michael Carbonara
Schedule of debt and/or equity financings	On August 14, 2020, the Board amended the MCPP, providing for the additional grant of common stock of the Company to each Dr. Maria I. Mitrani and Ian Bothwell based on the Company obtaining aggregate gross fundings (grants for research and development and clinical trials, purchase contracts for Company products, debt and/or equity financings) or other financial awards during the term of employment with the Company based on the amounts indicated below: Aggregate Funding Amount Shares From To $ 2,500,000 $ 5,000,000 5,000,000 $ 5,000,001 $ 10,000,000 10,000,000 $ 10,000,001 $ 30,000,000 30,000,000
Schedule of management and consultants performance stock plan	Pursuant to the MCPP, a total of 326,000,000 shares have been issued and as described above, additional shares are authorized to be issued under the MCPP subject to the achievement of the defined contingent performance based milestones described above and provided the milestones are achieved while the individual is employed and/or serving as a member of the Board: MCPP Shares Name Awarded Albert Mitrani 75,000,000 Ian Bothwell 75,000,000 Dr. Maria I. Mitrani 75,000,000 Dr. George Shapiro 68,000,000 Consultants 33,000,000 Total 326,000,000

WARRANTS (Tables)

WARRANTS (Tables)	3 Months Ended
	Jan. 31, 2021
Warrants
Summary of Warrant Activity	A summary of warrant activity for the three months ended January 31, 2021 and 2020 are presented below. Number of Weighted-average Remaining Aggregate Outstanding at October 31, 2020 9,500,000 $ 0.03 7.90 $ 1,268,000 Granted — $ — — $ — Exercised — $ — — $ — Expired/Forfeited — $ — — $ — Outstanding and exercisable at January 31, 2021 9,500,000 $ 0.03 7.65 $ 546,000 Number of Weighted-average Remaining Aggregate Outstanding at October 31, 2019 4,529,371 $ 0.20 0.30 $ — Granted — $ — — $ — Exercised — $ — — $ — Expired/Forfeited (1,271,428 ) $ 0.15 — $ — Outstanding and exercisable at January 31, 2020 3,257,943 $ 0.22 0.08 $ —

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	3 Months Ended
	Jan. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Schedule of adjustment revenues	Monthly Revenues (in millions) Base Salary Increase $ 1.00 $ 130,000 $ 1.50 $ 200,000 $ 2.00 $ 275,000 $ 3.50 $ 630,000 $ 5.00 $ 900,000

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended
	Jan. 31, 2021	Jan. 31, 2020	Oct. 31, 2020
FDIC limits per institutions	$ 250,000
Research and Development Expense	$ 662,000	$ 72,000
Common stock, shares authorized	2,500,000,000		2,500,000,000
Common stock, shares issued	1,010,132,783		939,942,783
Common stock, shares outstanding	1,010,132,783		939,942,783
Bad debt expense	$ 0	$ 0
Minimum [Member]
Property and equipment estimated useful lives	3 years
Maximum [Member]
Property and equipment estimated useful lives	15 years
Common Shares Issuable Upon Exercise of Warrants [Member]
Antidilutive securities excluded from computation of earnings per share	9,500,000	3,257,943

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended
	Jan. 31, 2021	Jan. 31, 2020	Oct. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Loss from operations	$ (8,165,361)	$ (688,785)
Accumulated deficit	(37,018,194)		$ (28,868,189)
Working capital deficit	$ (3,229,217)

INVENTORIES (Details)

INVENTORIES (Details) - USD ($)	Jan. 31, 2021	Oct. 31, 2020
Inventory Disclosure [Abstract]
Raw materials and supplies	$ 23,321	$ 26,199
Finished goods	125,102	120,612
Total Inventories	$ 148,423	$ 146,811

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($)	Jan. 31, 2021	Oct. 31, 2020
Property and equipment, gross	$ 465,942	$ 419,678
Less: accumulated depreciation and amortization	(66,636)	(54,444)
Total property and equipment, net	399,306	365,234
Computer Equipment [Member]
Property and equipment, gross	8,653	8,653
Finance lease equipment [Member]
Property and equipment, gross	239,595	239,595
Manufacturing Equipment [Member]
Property and equipment, gross	$ 217,694	$ 171,430

PROPERTY AND EQUIPMENT (Detai_2

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended		5 Months Ended
	Jan. 31, 2021	Jan. 31, 2020	Mar. 31, 2019
Depreciation expense	$ 12,192	$ 6,434
Lease Agreement [Member]
Lab equipment			$ 239,595
Annual interest rate			4.50%
Estimated useful lives of leased equipment			15 years

LEASE OBLIGATIONS (Details Narr

LEASE OBLIGATIONS (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		5 Months Ended
	Oct. 02, 2020	Jan. 31, 2021	Jan. 31, 2020	Mar. 31, 2019	Oct. 31, 2020	Jul. 31, 2020	Nov. 30, 2019	Feb. 28, 2019	Nov. 02, 2018
Security deposit		$ 20,782			$ 17,800
Lease expense		9,350	$ 8,475
MariLuna [Member]
Minimum monthly lease payments	$ 6,500								$ 3,500
Security deposit	$ 11,000	$ 5,000
Operating lease obligation						$ 117,659
Borrowing rate						4.50%
Lease expiration date	Sep. 30, 2021
Lease term						36 months
Miami Lab Lease Agreement [Member]
Minimum monthly lease payments							$ 4,400	$ 5,200
Security deposit								$ 6,332
Lease Agreement [Member]
Lab equipment				$ 239,595
Annual interest rate				4.50%
Estimated useful lives of leased equipment				15 years

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	1 Months Ended						3 Months Ended
	Feb. 28, 2021	Feb. 22, 2021	Jan. 31, 2021	Dec. 31, 2020	Dec. 21, 2020	Oct. 31, 2020	Jan. 31, 2021	Jan. 31, 2020	Oct. 02, 2020
Security deposit			$ 20,782			$ 17,800	$ 20,782
Rent expenses							10,500	$ 8,700
Payment for rent							8,270
Share based compensation							6,623,705	$ 93,484
Issuance of common stock	50,000		240,000	25,000
Shares issued	50,000		240,000	25,000
Director [Member]
Proceed from sale of products							10,400
Albert Mitrani [Member]
Accrued salary			$ 307,388				307,388
Dr. Mari Mitrani [Member]
Accrued salary			295,555				295,555
Issuance of common stock				47,675,000
Common stock granted					15,000,000
Shares issued				47,675,000
Ian Bothwell [Member]
Accrued salary			725,340				725,340
Dr. George Shapiro[Member]
Accrued consulting fees			75,396				75,396
Chief Medical Officer [Member]
Share based compensation							$ 82,250
Issuance of common stock							500,000
Shares issued							500,000
Mr. Mitrani [Member]
Share based compensation							$ 5,721,000
Issuance of common stock				47,675,000
Common stock granted					15,000,000
Shares issued				47,675,000
Dr. Allen Meglin [Member]
Common stock granted					1,000,000
Mr. Bothwell [Member]
Issuance of common stock				47,675,000
Common stock granted					15,000,000
Shares issued				47,675,000
Mr. Carbonara [Member]
Common stock granted					1,000,000
Second Lease Agreement [Member]
Monthly rent expense						$ 6,500
Security deposit			11,000				11,000
Rent expenses							19,500
MariLuna [Member]
Monthly rent expense							3,500
Security deposit			$ 5,000				5,000		$ 11,000
Management Services Organization [Member]
Proceed from sale of products							$ 333,760
Republic Asset Holdings LLC [Member]
Issuance of common stock		100,000
Sale of stock		1,818,181
Share Price		$ 0.055
Shares issued		100,000

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - USD ($)	1 Months Ended			3 Months Ended
	Oct. 31, 2020	Jun. 25, 2020	Feb. 19, 2019	Jan. 31, 2021	Jan. 31, 2020	Oct. 31, 2018	Jun. 20, 2018
Repayment of notes payable				$ 27,307	$ 23,904
General Surgical Florida [Member]
Interest rate			45.67%
Line of credit			$ 100,000
Repayment of line of credit			$ 132,160
Accredited Investors [Member]
Debt principal amount							$ 150,000
Interest rate							6.00%
Debt outstanding				144,000
Accrued interest				720
Two Accredited Investors [Member]
Debt principal amount						$ 70,000
Interest rate						6.00%
Accredited Investor 1 [Member] | Settlement and General Release Agreement [Member]
Debt principal amount		$ 50,000
Periodic payments		$ 6,250
Frequency of periodic payment		Monthly
Repayment of notes payable		$ 50,000
Accredited Investor 2 [Member] | Settlement and General Release Agreement [Member]
Debt principal amount				$ 20,000
Debt conversion, converted instrument, amount	$ 20,300
Debt conversion, converted instrument, shares issued	160,000
Debt conversion, original amount	$ 20,000
Debt conversion price per share				$ 0.125

IRS PENALTIES (Details Narrativ

IRS PENALTIES (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Jan. 31, 2021	Oct. 31, 2011	Oct. 31, 2020
Income Tax Disclosure [Abstract]
Penalties	$ 90,000	$ 20,000
Accrued tax penalties	$ 70,000		$ 70,000

CAPITAL STOCK (Details - Minimu

CAPITAL STOCK (Details - Minimum pre-Transaction price per share)	3 Months Ended
	Jan. 31, 2021$ / sharesshares
$0.22
Pre-transaction price per share valuation | $ / shares	$ 0.22	[1]
Executive bonus shares issued	40,000,000	[2]
Non-executive board bonus shares issued	2,000,000	[3]
$0.34
Pre-transaction price per share valuation | $ / shares	$ 0.34	[1]
Executive bonus shares issued	60,000,000	[2]
Non-executive board bonus shares issued	3,000,000	[3]
$0.45
Pre-transaction price per share valuation | $ / shares	$ 0.45	[1]
Executive bonus shares issued	80,000,000	[2]
Non-executive board bonus shares issued	4,000,000	[3]
$0.54
Pre-transaction price per share valuation | $ / shares	$ 0.54	[1]
Executive bonus shares issued	100,000,000	[2]
Non-executive board bonus shares issued	5,000,000	[3]
[1]	proforma for issuance of all shares to be issued pursuant to the MCPP and other in the money contingent share issuances
[2]	per each executive consisting of Albert Mitrani, Dr. Mari Mitrani, Ian Bothwell, and Dr. George Shapiro
[3]	per each non-executive Board member consisting of Dr. Allen Meglin and Michael Carbonara

CAPITAL STOCK (Details - Debt a

CAPITAL STOCK (Details - Debt and/or equity financings)	3 Months Ended
	Jan. 31, 2021USD ($)shares
Range 1 [Member]
Aggregate funding amount, minimum	$ 2,500,000
Aggregate funding amount, maximum	$ 5,000,000
Shares | shares	5,000,000
Range 2 [Member]
Aggregate funding amount, minimum	$ 5,000,001
Aggregate funding amount, maximum	$ 10,000,000
Shares | shares	10,000,000
Range 3 [Member]
Aggregate funding amount, minimum	$ 10,000,001
Aggregate funding amount, maximum	$ 30,000,000
Shares | shares	30,000,000

CAPITAL STOCK (Details - Manage

CAPITAL STOCK (Details - Management and consultants performance stock plan)	3 Months Ended
	Jan. 31, 2021shares
Mcpp shares awarded	326,000,000
Albert Mitrani
Mcpp shares awarded	75,000,000
Ian Bothwell [Member]
Mcpp shares awarded	75,000,000
Maria I. Mitrani [Member]
Mcpp shares awarded	75,000,000
George Shapiro [Member]
Mcpp shares awarded	68,000,000
Consultants [Member]
Mcpp shares awarded	33,000,000

CAPITAL STOCK (Details Narrativ

CAPITAL STOCK (Details Narrative) - USD ($)	Feb. 10, 2021	Jan. 04, 2021	Apr. 30, 2021	Feb. 28, 2021	Feb. 22, 2021	Jan. 31, 2021	Dec. 31, 2020	Dec. 21, 2020	Nov. 30, 2020	Sep. 23, 2020	Apr. 25, 2020	Apr. 30, 2021	Jan. 31, 2021	Jan. 31, 2020	Oct. 31, 2020
Preferred stock, shares authorized						10,000,000							10,000,000
Preferred stock, par value						$ 0.001							$ 0.001
Preferred stock, shares issued						0							0
Preferred stock, shares outstanding						0							0
Common stock, shares authorized						2,500,000,000							2,500,000,000		2,500,000,000
Stock-based compensation expense													$ 6,623,705	$ 93,484
Stock issued during period, shares, new issues				50,000		240,000	25,000
Stock-based compensation expense													$ 240,000
MCPP [Member]
Common stock shares sold during the period													16,500,000
Stock-based compensation expense													$ 445,500
Common stock granted											205,000,000
Stock issued during period, shares, new issues													326,000,000
Shares authorized under plan						326,000,000							326,000,000
Third Party [Member]
Stock issued for services, shares				500,000
CMO [Member]
Stock issued for services, shares				500,000
Stock issued for services, value				$ 82,250
Mr. Mitrani [Member]
Stock-based compensation expense													$ 5,721,000
Common stock granted								15,000,000
Stock issued during period, shares, new issues							47,675,000
Accredited Investors [Member]
Common stock shares sold during the period									800,000
Proceeds from issuance of common stock									$ 40,000
Sale of stock, price per share									$ 0.05
Consultant [Member] | Consultants Agreement [Member]
Shares vested									2,000,000
Sales Executives [Member]
Stock-based compensation expense													$ 290,000
Share price						$ 0.145							$ 0.145
One Individual [Member]
Stock-based compensation expense													$ 36,225
Share price									$ 0.145
Stock issued for services, shares									250,000
Dr. Mari Mitrani [Member]
Common stock granted								15,000,000
Stock issued during period, shares, new issues							47,675,000
Mr. Bothwell [Member]
Common stock granted								15,000,000
Stock issued during period, shares, new issues							47,675,000
Albert Mitrani [Member] | MCPP [Member]
Common stock granted										15,000,000
Share price										$ 0.25
Dr. Maria I. Mitrani [Member] | MCPP [Member]
Common stock granted										7,500,000
Share price										$ 0.50
Bothwell [Member] | MCPP [Member]
Common stock granted										15,000,000
Share price										$ 0.75
Subsequent Event [Member]
Stock-based compensation expense												$ 7,875
Subsequent Event [Member] | MCPP [Member]
Common stock shares sold during the period	16,500,000
Stock-based compensation expense												$ 445,500
Subsequent Event [Member] | Five Accredited Investors [Member]
Common stock shares sold during the period				12,340,910
Proceeds from issuance of common stock				$ 665,000
Sale of stock, price per share				$ 0.06
Subsequent Event [Member] | Republic Asset Holdings LLC [Member]
Common stock shares sold during the period					1,818,181
Proceeds from issuance of common stock					$ 100,000
Sale of stock, price per share					$ 0.055
Stock-based compensation expense			$ 56,364
Board of Directors [Member]
Voting right, percentage		Voting equivalency of 53.55%						Voting equivalency of 53.55%
Executive Management [Member]
Stock issued during period, shares, new issues							45,000,000
Non-executive Board Members [Member]
Stock issued during period, shares, new issues							2,000,000
Administrative Staff [Member]
Stock issued during period, shares, new issues							550,000
Medical Advisors [Member]
Stock issued during period, shares, new issues							125,000

WARRANTS (Details - Warrant Act

WARRANTS (Details - Warrant Activity) - Warrant [Member] - USD ($)	3 Months Ended
	Jan. 31, 2021	Jan. 31, 2020	Oct. 31, 2020
Number of Shares Outstanding beginning balance	9,500,000	4,529,371
Number of Shares, Granted	0	0
Number of Shares, Exercised	0	0
Number of Shares, Expired/Forfeited	0	(1,271,428)
Number of Shares Outstanding ending balance	9,500,000	3,257,943
Number of shares Exercisable	9,500,000		3,257,943
Weighted-average Exercise Price Outstanding beginning balance	$ 0.03	$ 0.20
Weighted-average Exercise Price, Granted	0	0
Weighted-average Exercise Price, Exercised	0	0
Weighted-average Exercise Price, Expired/Forfeited	0	0.15
Weighted-average Exercise Price Outstanding ending balance	0.03	$ 0.22
Weighted-average Exercise Price, Exercisable	$ 0.03		$ 0.22
Remaining Contractual Term (years) Outstanding beginning balance	7 years 10 months 25 days	3 months 19 days
Remaining Contractual Term (years) Outstanding ending balance	7 years 7 months 24 days	29 days
Remaining Contractual Term (years), Exercisable	7 years 7 months 24 days	29 days
Aggregate Intrinsic Value Outstanding beginning balance	$ 1,268,000	$ 0
Aggregate Intrinsic Value, Granted	0	0
Aggregate Intrinsic Value, Exercised	0	0
Aggregate Intrinsic Value, Expired/Forfeited	0	0
Aggregate Intrinsic Value Outstanding ending balance	546,000	$ 0
Aggregate Intrinsic Value, Exercisabe	$ 546,000		$ 0

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details - Adjustment of revenues) - USD ($)	3 Months Ended
	Jan. 31, 2021	Jan. 31, 2020
Monthly Revenues	$ 1,368,440	$ 696,948
Revenue 1 [Member]
Monthly Revenues	1,000,000
Base Salary Increase	130,000
Revenue 2 [Member]
Monthly Revenues	1,500,000
Base Salary Increase	200,000
Revenue 3 [Member]
Monthly Revenues	2,000,000
Base Salary Increase	275,000
Revenue 4 [Member]
Monthly Revenues	3,500,000
Base Salary Increase	630,000
Revenue 5 [Member]
Monthly Revenues	5,000,000
Base Salary Increase	$ 900,000

COMMITMENTS AND CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	Jan. 06, 2020	Jan. 31, 2021	Nov. 30, 2020	Oct. 31, 2020	Apr. 25, 2020	Mar. 30, 2020	Apr. 30, 2018	Jan. 31, 2021	Jan. 31, 2020	Feb. 26, 2020	Dec. 31, 2019
Bonus											$ 37,500
Base salary, description					An increase in base annual salary from $162,500 to $300,000. The amended salary amount of $300,000 shall be retroactively adjusted to commence as of January 1, 2019. The increased annual salary of $137,500 (“Incremental Salary”) over the prior annual salary amount of $162,500 (“Original Base Salary”) shall only be paid only upon there being sufficient available cash.
Accrued salary		$ 721,415						$ 721,415			$ 378,083
Stock-based compensation expense								6,623,705	$ 93,484
Order Execution [Member]
Payment for services		147,363	$ 195,524
Ian T. Bothwell [Member]
Warrant to purchase shares of common stock										7,500,000
Exercise price of warrants										$ 0.28
Executive Employment Agreement [Member] | A. Mitrani [Member]
Base salary							$ 162,500
Expenses allowances							5,000
Executive Employment Agreement [Member] | Ian T. Bothwell [Member]
Base salary							162,500
Executive Employment Agreement [Member] | Dr. Maria Ines Mitrani [Member]
Base salary							$ 162,500
VP Agreement [Member] | Vice President [Member]
Monthly salary	$ 18,000
Stock-based compensation expense								$ 94,500
Number of common stock issued	750,000
Shares vested								2,700,000
Common stock share price	$ 0.035
Consulting Agreement [Member]
Monthly salary				$ 12,500
Stock-based compensation expense				$ 875,000
Number of common stock issued				5,000,000
Consulting Agreement [Member] | Consultant [Member]
Monthly salary						$ 30,000
Number of common stock issued						12,000,000
CRO [Member]
Payment for services		476,943	$ 777,714
Expenses								$ 432,000
Outstanding expenses		$ 432,000						$ 432,000

SEGMENT INFORMATION (Details Na

SEGMENT INFORMATION (Details Narrative) - Integer	3 Months Ended
	Jan. 31, 2021	Jan. 31, 2020
Segment Reporting [Abstract]
Number of operating segments	1	1